Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: A quantitative analysis from the ADVANCE MPI trials
Total and reversible left ventricular (LV) perfusion defect size (PDS) predict patient outcome. Limited data exist as to whether regadenoson induces similar perfusion abnormalities as observed with adenosine. We sought to determine whether regadenoson induces a similar LV PDS as seen with adenosine across varying patient populations.
Methods and Results
ADVANCE MPI were prospective, double-blind randomized trials comparing regadenoson to standard adenosine myocardial perfusion tomography (SPECT). Following an initial adenosine SPECT, patients were randomized to either regadenoson (N = 1284) or a second adenosine study (N = 660). SPECT quantification was performed blinded to randomization and image sequence. Propensity analysis was used to define comparability of regadenoson and adenosine perfusion results. Baseline clinical and SPECT results were similar in the two randomized groups. There was a close correlation between adenosine and regadenoson-induced total (r 2 = 0.98, P < .001) and reversible (r 2 = 0.92, P < .001) PDS. Serial differences in total (0.00 ± 3.51 vs −0.11 ± 3.46, P = .51) and reversible (0.15 ± 3.79 vs 0.07 ± 3.33, P = .65) PDS were also comparable in patients randomized to regadenoson vs adenosine, respectively, and irrespective of age, gender, diabetic status, body mass index, or prior cardiovascular history. By propensity analysis, regadenoson-induced total PDS was significantly larger than observed with adenosine.
This is the first study to show that regadenoson induces similar, if not larger, perfusion defects than those observed with adenosine across different patient populations and demonstrates the value of quantitative analysis for defining serial changes in SPECT perfusion results. Regadenoson should provide comparable diagnostic and prognostic SPECT information to that obtained with adenosine.
KeywordsA2A adenosine receptor agonists myocardial perfusion imaging: SPECT vasodilator stress
Drs Mahmarian, Cerqueira, and Thomas are consultants and on the Speakers Bureau for Astellas Pharma, Inc. Dr Bateman has served on Astellas Advisory Boards and has received grant research support from Astellas. The other authors have no conflict of interest.
- 1.Zoghbi GJ, Iskandrian AE. Coronary artery disease detection: pharmacologic stress. In: Zaret BL, Beller GA, editors. Clinical nuclear cardiology: State of the art and future directions. 3rd ed. Philadelphia: Elsevier Mosby; 2005. p. 233-53.Google Scholar
- 3.Mahmarian JJ, Shaw LJ, Filipchuk NG, Dakik HA, Iskander SS, Ruddy TD, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol 2006;48:2448-57.PubMedCrossRefGoogle Scholar
- 5.Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine. A quantitative analysis from the ADVANCE MPI 2 Trial. J Am Coll Cardiol CV Imaging 2009;2:959-68.Google Scholar
- 10.Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008;117:1283-91.PubMedCrossRefGoogle Scholar
- 11.Mahmarian JJ, Dakik HA, Filipchuk NG, Shaw LJ, Iskander SS, Ruddy TD, et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 2006;48:2458-67.PubMedCrossRefGoogle Scholar
- 12.Mahmarian JJ. Monitoring Medical Therapy: The role of noninvasive imaging. In: Dilsizian V, Narula J, Braunwald E, editors. Atlas of nuclear cardiology. 2nd ed. Philadelphia, PA: Current Medicine; 2006. p. 191-210.Google Scholar
- 19.Kaul S, Jayaweera AR. Coronary and myocardial blood volumes. Non-invasive tools to assess the coronary microcirculation? Circulation 1996;96:719-24.Google Scholar
- 20.Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, On Behalf of the ADVANCE-MPI Trial Investigators. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. J Am Coll Cardiol CV Imaging 2008;1:307-16.Google Scholar
- 24.Rosenblatt J, Mooney D, Dunn T, Cohen M. Asystole following regadenoson infusion in stable outpatients. J Nucl Cardiol 2014. doi: 10.1007/s12350-014-9898-0.